FTISADTSK

• UNSPSC Description:

  FTISADTSK is an endogenous stable signature peptide from Trastuzumab monitored by selected reaction monitoring (SRM)[1].

• Target Antigen:

  Drug Metabolite

• Type:

  Peptides

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ftisadtsk.html

• Solubility:

  10 mM in H2O

• Smiles:

  O=C(N[C@@H](CO)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@H](C(O)=O)CCCCN)=O)=O)=O)=O)=O)[C@H]([C@@H](C)CC)NC([C@H]([C@H](O)C)NC([C@@H](N)CC1=CC=CC=C1)=O)=O

• Molecular Weight:

  969.05

• References & Citations:

  [1]Bults P, et al. LC-MS/MS-Based Monitoring of In Vivo Protein Biotransformation: Quantitative Determination of Trastuzumab and Its Deamidation Products in Human Plasma. Anal Chem. 2016;88(3):1871-1877.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1431957-73-1